<DOC>
	<DOC>NCT00967772</DOC>
	<brief_summary>The safety/tolerability and pharmacokinetics (PK) of Naftopidil (commercial name: Flivas) after oral administration will be investigated in Korean healthy male volunteers. All volunteers will be assigned to 2 groups and administered a lower single dose tablet (Period 1). After one week's wash-over period, the volunteers take higher dosages (Period 2).</brief_summary>
	<brief_title>The Safety/Tolerability and Pharmacokinetics (PKs) of Naftopidil in Korean Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Naftopidil</mesh_term>
	<criteria>Healthy males subjects, 2045 years inclusive Weight over 55 kg inclusive and Ideal Body Weight (IBW) between 20% and +20% inclusive Written informed consent given Hypersensitivity to drugs(aspirin, antibiotics and so on) including naftopidil History or presence of any clinically significant liver or kidney disease, gastrointestinal, cardiovascular, respiratory, endocrinal, musculoskeletal, neurologic/psychiatric, urinary, hematological, oncological pathology Have a history of drug abuse, or show positive for drug abuse at urine screening Have participated in another clinical study within 2 months prior to entering inth the study Are considered ineligible by the investigator due to clinical laboratory results or any other relevant reasons</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety</keyword>
	<keyword>tolerability</keyword>
</DOC>